Toshiki Masuishi

18PUBLICATIONS
96CO-AUTHORS
Cellular immunologyCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jun 19, 2026
Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with PD-L1 amplification: a case report.

|May 08, 2026
Predictive factors for early mortality after regorafenib or trifluridine/tipiracil initiation in metastatic colorectal cancer.

|Apr 13, 2026
Development of a visualization tool to estimate out-of-pocket costs for systemic cancer therapy in Japan and claims-based agreement evaluation: the VEST-Ca study.

Kazunori Honda, Kazuhiro Shimomura, Hiroya Taniguchi

|Jul 23, 2025
Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G).

Yuki Matsubara, Toshiki Masuishi, Waki Hosoda

|Jun 12, 2025
Facial Skin With Conspicuous Enlarged Pores Closely Related to Severity of Facial Acneiform Rash and Therapeutic Effects of EGFR Inhibitors in RAS Wild-Type Metastatic Colorectal Cancer: Ancillary Analysis of FAEISS Study (NCCH1512).

Shusuke Yoshikawa, Katsuko Kikuchi, Keiko Nozawa

|Feb 13, 2025
BRAF V600E and Non-V600E Mutations in RAS Wild-Type Metastatic Colorectal Cancer: Prognostic and Therapeutic Insights from a Nationwide, Multicenter, Observational Study (J-BROS).

Hiroya Taniguchi, Kay Uehara, Toshiaki Ishikawa

Pageof 3

Frequent Collaborators

6 joint publications

Takayuki Yoshino

5 joint publications

Hiroya Taniguchi

3 joint publications

Yasunobu Ishizuka

3 joint publications

Yoshito Komatsu